Pablo E. Pérgola

12.0k total citations · 6 hit papers
135 papers, 7.1k citations indexed

About

Pablo E. Pérgola is a scholar working on Nephrology, Hematology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Pablo E. Pérgola has authored 135 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Nephrology, 37 papers in Hematology and 31 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Pablo E. Pérgola's work include Erythropoietin and Anemia Treatment (32 papers), Iron Metabolism and Disorders (23 papers) and Dialysis and Renal Disease Management (20 papers). Pablo E. Pérgola is often cited by papers focused on Erythropoietin and Anemia Treatment (32 papers), Iron Metabolism and Disorders (23 papers) and Dialysis and Renal Disease Management (20 papers). Pablo E. Pérgola collaborates with scholars based in United States, Canada and Australia. Pablo E. Pérgola's co-authors include Stacey Ruiz, Dean L. Kellogg, John M. Johnson, Nosratola D. Vaziri, Richard A. Zager, Colin J. Meyer, Oscar Benavente, Geoffrey A. Block, Melissa Krauth and Leslie A. McClure and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Pablo E. Pérgola

130 papers receiving 7.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

2011 707 citations Pablo E. Pérgola, Colin J. Meyer et al. profile →
Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

2013 596 citations Stacey Ruiz, Pablo E. Pérgola et al. Kidney International profile →
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial

2013 481 citations Oscar Benavente, Christopher S. Coffey et al. The Lancet profile →
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

2021 433 citations Matt Devalaraja, Larry Lo et al. The Lancet profile →
Sodium Zirconium Cyclosilicate in Hyperkalemia

2014 352 citations Geoffrey A. Block, Pablo E. Pérgola et al. profile →
Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment

2020 191 citations Pinelopi P. Kapitsinou, Pablo E. Pérgola et al. Journal of the American Society of Nephrology profile →

Peers

Countries citing papers authored by Pablo E. Pérgola

Since Specialization

Citations

This map shows the geographic impact of Pablo E. Pérgola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo E. Pérgola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo E. Pérgola more than expected).

Fields of papers citing papers by Pablo E. Pérgola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo E. Pérgola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo E. Pérgola. The network helps show where Pablo E. Pérgola may publish in the future.

Co-authorship network of co-authors of Pablo E. Pérgola

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo E. Pérgola. A scholar is included among the top collaborators of Pablo E. Pérgola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo E. Pérgola. Pablo E. Pérgola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study 2024 ·Kidney360 ·Stuart M. Sprague, Daniel E. Weiner, (unknown), Pablo E. Pérgola, Steven Fishbane, Geoffrey A. Block, (unknown), Stephen Z. Fadem, Robert I. Lynn, George Z. Fadda, (unknown), (unknown), (unknown), David M. Spiegel, David P. Rosenbaum	7
2	Selonsertib in Patients with Diabetic Kidney Disease 2024 ·Journal of the American Society of Nephrology ·Hiddo J.L. Heerspink, Vlado Perkovic, Katherine R. Tuttle, Pablo E. Pérgola, Kenneth W. Mahaffey, Uptal D. Patel, Julie H. Ishida, Albert Y. Kuo, Chen Fang, Robert P. Kustra, (unknown), Peter Rossing, Naoki Kashihara, Glenn M. Chertow	6
3	Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), Tomas Ganz, Pablo E. Pérgola, (unknown), Kevin Dykstra	3
4	Effect of Avenciguat on Albuminuria in Patients with CKD 2024 ·Journal of the American Society of Nephrology ·Hiddo J.L. Heerspink, David Cherney, Abdul Halim Abdul Gafor, José Luis Górriz, Pablo E. Pérgola, Sydney Tang, (unknown), Hristo Iliev, Zhichao Sun, Dominik Steubl, Masaomi Nangaku	21
5	Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD 2022 ·Kidney360 ·Pablo E. Pérgola, Chaim Charytan, Dustin J. Little, (unknown), Lynda A. Szczech, Robert Leong, Steven Fishbane	13
6	Phosphate Frustration: Treatment Options to Complement Current Therapies 2022 ·International Journal of Nephrology ·Pablo E. Pérgola	3
7	Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study 2022 ·Nephrology Dialysis Transplantation ·Luís M. Ruilope, Bertram Pitt, Stefan D. Anker, Peter Rossing, Csaba P. Kövesdy, Roberto Pecoits‐Filho, Pablo E. Pérgola, Amer Joseph, Andrea Lage, (unknown), Markus F. Scheerer, George L. Bakris	39
8	Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion 2021 ·Journal of Clinical Medicine ·Carsten Schmidt, Stephen Allen, Nelson Kopyt, Pablo E. Pérgola	9
9	Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting 2021 ·Journal of Renal Nutrition ·Steven Fishbane, David M. Charytan, Glenn M. Chertow, Martin L. Ford, Csaba P. Kövesdy, Pablo E. Pérgola, Carol A. Pollock, Bruce Spinowitz	10
10	Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease 2021 ·American Journal of Nephrology ·Pablo E. Pérgola, Diogo Belo, Paul Crawford, Moustafa Sherief Moustafa, Wei Luo, Alexander S. Goldfarb‐Rumyantzev, Youssef M.K. Farag	2
11	Roxadustat vs. Placebo or Epoetin Alfa Has No Clinically Meaningful Effect on Blood Pressure in Patients with Anemia of CKD 2020 ·Journal of the American Society of Nephrology ·Tak Mao Chan, Roberto Pecoits‐Filho, Anjay Rastogi, Pablo E. Pérgola, (unknown), Ming Zhong, Lynda A. Szczech, Kin-Hung P. Yu	2
12	Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment breakdown → 2020 ·Journal of the American Society of Nephrology ·(unknown), Pinelopi P. Kapitsinou, Pablo E. Pérgola, Csaba P. Kövesdy, Diana Jalal	191
13	Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial 2020 ·Journal of the American Society of Nephrology ·Pablo E. Pérgola, Matt Devalaraja, Steven Fishbane, Michel Chonchol, Vandana Mathur, Mark T. Smith, Larry Lo, (unknown), Rahul Kakkar, Michael Davidson	54
14	Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review 2019 ·Journal of Medical Economics ·Bruce Spinowitz, Roberto Pecoits‐Filho, Wolfgang C. Winkelmayer, Pablo E. Pérgola, (unknown), Philippe Thompson‐Leduc, Patrick Lefèbvre, (unknown), Ana Bozas, (unknown), Holly B. Krasa	45
15	Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease 2016 ·Kidney International ·Pablo E. Pérgola, Bruce Spinowitz, (unknown), Bradley J. Maroni, Volker H. Haase	184
16	Lacunar Strokes in Patients With Diabetes Mellitus: Risk Factors, Infarct Location, and Prognosis 2014 ·Stroke ·S. del Palacio, Leslie A. McClure, Oscar Benavente, Carlos Bazan, Pablo E. Pérgola, Robert G. Hart	68
17	Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial breakdown → 2013 ·The Lancet ·(unknown), Oscar Benavente, Christopher S. Coffey, Robin Conwit, Robert G. Hart, Leslie A. McClure, Lesly A. Pearce, Pablo E. Pérgola	481
18	Blood Pressure After Recent Stroke: Baseline Findings From the Secondary Prevention of Small Subcortical Strokes Trial 2013 ·American Journal of Hypertension ·Carole L. White, Pablo E. Pérgola, Jeff M. Szychowski, Robert L. Talbert, Amin Cervantes‐Arriaga, Heather D. Clark, Óscar H. Del Brutto, Iván Godoy, Michael D. Hill, A. Pelegrí, Caroline R. Sussman, Addison A. Taylor, J. Valdivia, David C. Anderson, Robin Conwit, Oscar Benavente, (unknown)	28
19	Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD 2011 ·American Journal of Nephrology ·Pablo E. Pérgola, Melissa Krauth, Jesse W. Huff, Deborah A. Ferguson, Stacey Ruiz, Colin J. Meyer, David G. Warnock	197
20	Atrial natriuretic peptide, vasoactive intestinal peptide, and skin blood flow during heat stress in humans 1996 ·The FASEB Journal ·(unknown), Pablo E. Pérgola, (unknown), (unknown), Deepak E. Solomon, Joyce M. Johnson	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact